Skip to main content
SpringerLink
Log in

Clofarabine and CY do not yield reliable engraftment of hematopoietic stem cells

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Saven A, Saven A . Fludarabine treatment and transfusion-associated graft-versus-host disease. Lancet 1996; 348: 473.

    Article  CAS  PubMed  Google Scholar 

  2. Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009; 27: 4392–4397.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28: 549–555.

    Article  CAS  PubMed  Google Scholar 

  4. Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003; 9: 6335–6342.

    CAS  PubMed  Google Scholar 

  5. Claxton DF, Ehmann C, Rybka W, Claxton DF, Ehmann C, Rybka W . Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130: 256–264.

    Article  CAS  PubMed  Google Scholar 

  6. van Besien K, Locke F, Kline J, Godley L, Larson RA, Odenike O et al. Clofarabine-Melphalan-Alemtuzumab conditioning for allogeneic hematopoietic cell transplantation (Hct) in patients with advanced hematologic malignancies: A Phase I-II study. Blood (ASH Annual Meeting Abstracts) 2008; 112: 4381.

    Google Scholar 

  7. Kirschbaum M, Stein AS, Frankel P, Popplewell L, Chen R, Delioukina ML et al. Final report of a phase I study of clofarabine plus high dose melphalan as a conditioning regimen for allogeneic transplantation. Blood (ASH Annual Meeting Abstracts) 2010; 116: 528.

    Google Scholar 

  8. Kebriaei P, Ledesma C, Culotta K, Shpall EJ, Ciurea SO, Alousi AM et al. Clofarabine (Clo) and busulfan (Bu) as a novel reduced toxicity Conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients (pts) with acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2010; 116: 3484.

    Google Scholar 

  9. Mineishi S, Magenau J, Tobai H, Pawarode A, Peres EM, Reddy P et al. Allogeneic hematopoietic stem cell transplantation with clofarabine/busulfan × 4 (CloBu4) conditioning exhibits significant anti-tumor activity in non—remission hematologic malignancies, especially in AML. Blood (ASH Annual Meeting Abstracts) 2010; 116: 35.

    Google Scholar 

  10. Agura E, Berryman RB, Pineiro L, Vance E, Tadic-Ovcina M, Woelfel RG et al. Preliminary results of phase II trial of clofarabine with parenteral busulfan (CLO/BU) followed by allogeneic related or unrelated donor transplantation for the treatment of hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: S298–S299.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Hematology/Oncology Division, Penn State College of Medicine, Hershey, PA, USA

    J Karch, J Zhu, W C Ehmann & D Claxton

Authors
  1. J Karch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W C Ehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Claxton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Claxton.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karch, J., Zhu, J., Ehmann, W. et al. Clofarabine and CY do not yield reliable engraftment of hematopoietic stem cells. Bone Marrow Transplant 47, 1134–1135 (2012). https://doi.org/10.1038/bmt.2011.224

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.224

  • Springer Nature Limited

This article is cited by

Search

Navigation